These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24639436)

  • 1. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.
    Gresle MM; Liu Y; Dagley LF; Haartsen J; Pearson F; Purcell AW; Laverick L; Petzold A; Lucas RM; Van der Walt A; Prime H; Morris DR; Taylor BV; ; Shaw G; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1209-13. PubMed ID: 24639436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Phosphorylated Neurofilament Heavy Chain Level in Relapsing Remitting Multiple Sclerosis in Correlation to Disease Activity and Disability.
    Shehab AA; Solima DA; Abdel-Hafeez MA; Mohamed SM
    Egypt J Immunol; 2019 Jan; 26(1):1-13. PubMed ID: 31332992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Validation Study of Neurofilament Heavy Chain and 8-hydroxy-2'-deoxyguanosine as Plasma Biomarkers of Clinical/Paraclinical Activity in First and Relapsing-Remitting Demyelination Acute Attacks.
    Ljubisavljevic S; Stojanovic I; Basic J; Pavlovic DA
    Neurotox Res; 2016 Oct; 30(3):530-8. PubMed ID: 27295058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
    Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
    Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel Cerebrospinal Fluid and Serum Temporal Profile Assessment of Axonal Injury Biomarkers Neurofilament-Light Chain and Phosphorylated Neurofilament-Heavy Chain: Associations With Patient Outcome in Moderate-Severe Traumatic Brain Injury.
    Wang KKW; Barton DJ; McQuillan LE; Kobeissy F; Cai G; Xu H; Yang Z; Trifilio E; Williamson JB; Rubenstein R; Robertson CS; Wagner AK
    J Neurotrauma; 2024 Jul; 41(13-14):1609-1627. PubMed ID: 38588256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
    Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis.
    Boylan KB; Glass JD; Crook JE; Yang C; Thomas CS; Desaro P; Johnston A; Overstreet K; Kelly C; Polak M; Shaw G
    J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):467-72. PubMed ID: 23117489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.
    Silber E; Semra YK; Gregson NA; Sharief MK
    Neurology; 2002 May; 58(9):1372-81. PubMed ID: 12011283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes.
    Alexander JS; Chervenak R; Weinstock-Guttman B; Tsunoda I; Ramanathan M; Martinez N; Omura S; Sato F; Chaitanya GV; Minagar A; McGee J; Jennings MH; Monceaux C; Becker F; Cvek U; Trutschl M; Zivadinov R
    J Neurol Sci; 2015 Aug; 355(1-2):84-9. PubMed ID: 26073484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker.
    Boylan K; Yang C; Crook J; Overstreet K; Heckman M; Wang Y; Borchelt D; Shaw G
    J Neurochem; 2009 Dec; 111(5):1182-91. PubMed ID: 19765193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity.
    Ayrignac X; Le Bars E; Duflos C; Hirtz C; Maleska Maceski A; Carra-Dallière C; Charif M; Pinna F; Prin P; Menjot de Champfleur N; Deverdun J; Kober T; Marechal B; Fartaria MJ; Corredor Jerez R; Labauge P; Lehmann S
    Sci Rep; 2020 Jul; 10(1):10923. PubMed ID: 32616916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis.
    Gresle MM; Shaw G; Jarrott B; Alexandrou EN; Friedhuber A; Kilpatrick TJ; Butzkueven H
    J Neurosci Res; 2008 Dec; 86(16):3548-55. PubMed ID: 18709652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Yuceyar N; Taşkiran D; Sağduyu A
    Clin Neurol Neurosurg; 2001 Dec; 103(4):206-11. PubMed ID: 11714562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylated neurofilament subunit levels in the serum of cervical compressive myelopathy patients.
    Kato S; Chikuda H; Ohya J; Hayakawa K; Takeshita K; Tanaka S; Ogata T
    J Clin Neurosci; 2015 Oct; 22(10):1638-42. PubMed ID: 26195334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
    Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (1)H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis.
    Caramanos Z; DiMaio S; Narayanan S; Lapierre Y; Arnold DL
    J Neurol Sci; 2009 Jul; 282(1-2):72-9. PubMed ID: 19232641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.